Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft Model
The key objective of the study was to determine the single and multiple does toxicity and efficay of Bismuth-213 labeled PAI2 based targeted alpha therapy by selectively targeting uPA and uPAR in regressing prostate cancer in a nude mouse model.
RIZVI S.M.A.;
LI Y.;
SONG E.;
QU C.F.;
RAJA C.;
MORGENSTERN Alfred;
APOSTOLIDIS Christos;
ALLEN B.J.;
2006-11-03
LANDES BIOSCIENCE
JRC35141
Additional supporting files
| File name | Description | File type | |
|---|
